Loading...
•
Mar 31, 2023
Essa Pharma Q2 2023 Earnings Report
ESSA Pharma reported financial results for the fiscal second quarter ended March 31, 2023.
Key Takeaways
ESSA Pharma reported its cash position is expected to be sufficient to fund current and planned operations through 2025. The company continued to enroll patients into its Phase 1 study of EPI-7386 in combination with Xtandi® (enzalutamide).
Entered into a clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin in the second half of 2023.
Continued to enroll patients into the fourth cohort of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide); Phase 1 completion expected in 3Q2023 followed by the initiation of the randomized Phase 2 part of the study.
The Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients is ongoing.
Cash position is expected to be sufficient to fund current and planned operations through 2025.
Essa Pharma
Essa Pharma
Forward Guidance
The company's cash position is expected to be sufficient to fund current and planned operations through 2025.